Effect of continuous normalization of serum complement levels on clinically evident lupus nephritis

Background: Lupus Nephritis (LN) is one of the most common and serious manifestations in Systemic Lupus Erythematosus (SLE) patients that causes significant morbidity and mortality. Certain biomarkers for LN are sometimes able to assess treatment response of lupus nephritis. Objective: To compare serum complement levels (C3 & C4) as markers of treatment response of LN and their relation to the LN class in renal biopsy. Methods: This prospective observational study was conducted in the Department of Nephrology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from July 2018 to August 2019. Twenty seven patients who were diagnosed with lupus nephritis after kidney biopsy were included in this study. Serum complement levels (C3 & C4), 24 hours urinary total protein (24-hr UTP) and anti-double-stranded DNA (anti-ds DNA) were measured in all patients at baseline, 3 months and 6 months after treatment. These biomarker values before and after treatment were compared between the treatment response and non response groups. Results: Serum C3 levels were significantly different in patients of proliferative lupus nephritis (Class III & Class IV) than non proliferative lupus nephritis (Class V) at baseline (0.47 ± 0.32 vs0.89 ± 0.43g/l, p = 0.009) and levels changed significantly 6 months after treatment (p <0.001) and likewise for Serum C4 levels (0.10 ± 0.06 vs0.24 ± 0.26g/l, p = 0.040). Serum C3 levels were also found to correlate significantly with SLEDAI and renal SLEDAI. No significant difference was observed for 24-hr UTP levels at baseline between remission and non-remission groups. Conclusion: Serum C3 & C4 levels may be utilized as serological biomarkers to predict and monitor the treatment response of lupus nephritis.

Download Full-text

The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis

The American Journal of Medicine ◽

10.1016/0002-9343(78)90079-7 ◽

1978 ◽

Vol 64 (2) ◽

pp. A90

Keyword(s):

Lupus Nephritis ◽

Serum Complement

Download Full-text

The effect of continuous normalization of serum hemolytic complement on the course of lupus nephritis

The American Journal of Medicine ◽

10.1016/0002-9343(81)90870-6 ◽

1981 ◽

Vol 70 (5) ◽

pp. 1067-1072 ◽

Cited By ~ 18

Author(s):

Mark P. Jarrett ◽

Leonarda B. Sablay ◽

Leslie Walter ◽

Peter Barland ◽

Arthur I. Grayzel

Keyword(s):

Lupus Nephritis ◽

Continuous Normalization

Download Full-text

AB0954 Relationship between serum complement levels and renal pathological classification in children with silent lupus nephritis

10.1136/annrheumdis-2017-eular.1012 ◽

2017 ◽

Author(s):

H Wakiguchi ◽

T Kubota ◽

S Takei

Keyword(s):

Lupus Nephritis ◽

Serum Complement ◽

Pathological Classification

Download Full-text

Serum complement levels as prognostic marker for monitoring treatment response in lupus nephritis

BIRDEM Medical Journal ◽

10.3329/birdem.v11i2.53129 ◽

2021 ◽

Vol 11 (2) ◽

pp. 97-102

Author(s):

Saiful Bahar Khan ◽

Rafi Nazrul Islam ◽

Md Saif Bin Mizan ◽

AKM Shahidur Rahman ◽

Shah Md Zakir Hossain ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Nephritis ◽

Disease Activity ◽

Treatment Response ◽

Lupus Erythematosus ◽

Treatment Initiation ◽

Complement C3 ◽

P Value ◽

Serum Complement ◽

Systemic Lupus

Background: Lupus nephritis (LN) is one of the most common and serious manifestations of systemic lupus erythematosus (SLE) that causes significant morbidity and mortality. Certain biomarkers for LN are sometimes able to assess treatment response in lupus nephritis. This study aimed to compare serum complement levels (C3 and C4) as markers of treatment response of LN and their relation to the LN class in renal biopsy. Methods: This prospective observational study was conducted in the Department of Nephrology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from July 2018 to August 2019. Twenty seven patients who were diagnosed with LN after kidney biopsy were included in this study. Serum complement levels (C3 and C4), 24 hours urinary total protein (24-hr UTP) and anti-double-stranded DNA (anti-ds DNA) were measured in all patients at baseline, 3 months and 6 months after treatment initiation. These biomarker values before and after treatment were compared between the proliferative and non-proliferative LN patients. Results: Serum C3 levels were significantly different between patients with proliferative LN (Class III and Class IV) and non-proliferative LN (Class V) at baseline (0.47 ± 0.32 g/l versus 0.89 ± 0.43 g/l, p=0.009) and levels changed significantly 6 months after treatment initiation (p<0.001) and likewise for serum C4 levels (0.10 ± 0.06 g/l versus 0.24 ± 0.26 g/l, p=0.040). The values of 24-hr UTP and anti-ds-DNA were significantly different 6 months after treatment with p value <0.05 in both groups but C3 (p<0.001) and renal Systemic Lupus Erythematosus Disease Activity Index (rSLEDAI) (p<0.001) were only significant in the proliferative group. On the other hand, after 6 months treatment, C4 levels became relatively higher but that was not significant in both groups (p>0.05). Conclusion: After 6 months of treatment, serum C3 and C4 levels increased towards normal in both LN groups. Serum C3 and C4 levels in patients with LN correlate with disease activity. Therefore, serum complement (C3 and C4) levels may be utilized as serological biomarkers for treatment response of LN. Birdem Med J 2021; 11(2): 97-102

Download Full-text

MiR-384 is associated with renal damage in lupus nephritis via regulation of TET3 expression

Tropical Journal of Pharmaceutical Research ◽

10.4314/tjpr.v19i12.13 ◽

2021 ◽

Vol 19 (12) ◽

pp. 2571-2576

Author(s):

Jun Zhang ◽

Suli Lu ◽

Ting Ding ◽

Haijia Zhao ◽

Dongxing Tang

Keyword(s):

Lupus Nephritis ◽

Serum Creatinine ◽

Renal Damage ◽

Complement C3 ◽

Enzyme Linked Immunosorbent Assay ◽

Serum Complement ◽

Urine Protein ◽

Qrt Pcr ◽

Potential Biomarker ◽

Protein Serum

Purpose: To investigate the correlations between miR-384 expression and renal damage in lupus nephritis (LN).Methods: Lupus nephritis and normal tissues were collected during surgery. The relative miR-384 expression was evaluated by extracting RNA and performing quantitative real time PCR (qRT-PCR) assays. Expression of ten-eleven translocation (TET3) mRNA and protein were measured by qRT-PCR and western blotting, respectively. The 24-h urine protein, serum complement C3, and serum creatinine were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits. TargetScan and luciferase assays were used to validate the binding site for miR-384 and its target mRNA. Relationships among miR-384, TET3, and renal damage were analyzed by Spearman rank-order correlation coefficients.Results: MiR-384 expression increased in LN tissues and was positively correlated with the activity index (AI) and chronicity index of LN, whereas miR-384 expression and serum complement C3 were negatively correlated. Positive correlations were observed between miR-384 expression and 24-h urine protein, serum creatinine, and systemic lupus erythematosus disease AI. TargetScan and luciferaseassays indicated that the TET3 3′-UTR was the direct target of miR-384. MiR-384 upregulation inhibited TET3 mRNA and protein expression, and was negatively associated with renal damage in LN.Conclusion: MiR-384 upregulation contributes to renal damage in LN by targeting the 3′-UTR of TET3 mRNA, suggesting that miR-384 is a potential biomarker and therapeutic target in LN. Keywords: MiR-384, Renal damage, Lupus nephritis, Ten-eleven translocation, TET3

Download Full-text